HAPILA showcases advanced API development expertise at CPhI Worldwide Frankfurt
Press Release | HAPILA GmbH
OCTOBER 23, 2019
HAPILA will be an exhibitor in the API zone of the core CPhI expo, with a stand at booth A32 in Hall 4.2 of the Messe showground in Frankfurt-am-Main, shared with partner companies Enzymicals AG and RubiePharm Arzneimittel GmbH.
API synthesis scale-up
HAPILA’s display will feature its end-to-end capabilities to support development and manufacture of drug products with patented processes and in-depth experience in the API value-creation chain from synthesis through purification to particle design, enabling it to be a highly efficient bridge-builder between API production and pharmaceutical end-use.
In addition, HAPILA will show its ability to provide independent development and scale up of chemical API synthesis including analytical method development, manufacturing of reference substances and development of purification processes based on its patented HAPIpur® technology that fully automates continuous counter current crystallization.
The HAPILA team will be led by CEO Dr. Uwe Müller and Dr. Steffen Wittmann, Head of Quality Unit (QA/QC).
“We have been a constant presence at CPhI Worldwide for more than a decade and once again look forward to the superb opportunities this event provides to connect with our customers and new interested potential partners to discuss possibilities for interesting co-operations and explore new options,” said Dr. Müller
One stop shop offers
“We will be reaching out to decision makers and pragmatists within pharmaceutical companies performing own drug development as well as generic companies looking for outsourcing or external support and SME’s and start-ups developing new drugs who need to access API-experience in the field of small molecules,” Dr. Müller explained.
“For partners like these, we have an impressive one stop shop offer that includes deep experience in GMP-related development and GMP manufacturing, a full regulated service for APIs that respects requirements of IMPD and ASMF documentation, In house analytical investigations by our QC unit and the ability to take the drug from gram scale in the lab to full 100L pilot production,” said Dr. Wittmann.
About HAPILA GmbH
HAPILA GmbH is a Contract developer and manufacturer (CDMO) that provides high-value services to pharma, biotech and fine chemicals client companies in the development and cGMP manufacture of active pharmaceutical ingredients (APIs).
HAPILA is an independent company with particular experience in GMP-related development and GMP manufacturing, offering full regulated service for API (IMPD, ASMF) to very high scientific and quality assurance (QA) levels.
It supports the development and manufacture of drug products with patented processes and in-depth experience in the API value-creation chain from synthesis through purification to particle design.
The company’s mission is to supply exclusive products of highest quality, potency and safety in compliance with GMP and environmental protection guidelines. All HAPILA teamwork is focused on product quality and customer satisfaction.
All HAPILA chemical synthesis is carried out in-house at its GMP certified laboratories at Gera, Thuringia, in east-central Germany.
When combined with purification and particle design, HAPILA’s chemical synthesis services cover the complete API value-creation chain, enabling it to be a highly efficient bridge-builder between API production and pharmaceutical end-use.
About CPhI Worldwide 2019
CPhI Worldwide is the flagship annual trade show for pharma ingredients and partner sourcing providing delegates and exhibitors opportunities to arrange face-to-face meetings with potential international pharmaceutical partners and collaborators and gain insights on latest industry trends.
Now in its 30th year, the 2019 expo is a three-day event opening November 5 at the Messe showground in Frankfurt-am-Main, Germany, which last hosted CPhI in 2017.
CPhI Worldwide 2019 includes the co-located zoned exhibitions; ICSE Outsourcing solutions, P-MEC Machinery and Equipment, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and events and the new BioProduction conference focusing on bioprocessing and manufacturing.
Together, they are expected to attract 45,000 delegates along with more than 2,500 exhibiting companies from some 160 countries.
The CPhI series is staged by leading Global B2B Events Organizer and Publisher UBM Live More information at: https://www.cphi.com/europe/
Dr. Uwe Müller, CEO, HAPILA GmbH
Tel: +49 365 205 86 930